BridgeBio Pharma announced it will present new clinical data on acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), at the American Heart Association Scientific Sessions 2026. The data reinforce acoramidis as the first-line treatment choice for ATTR-CM, highlighting its near-complete stabilization of transthyretin. Acoramidis is approved under the brand names Attruby and BEYONTTRA in multiple regions including the US, Europe, and Japan. The presentations include studies on heart failure events, hospitalization risks, and diagnostic advancements, underscoring the drug's clinical benefits and safety profile.
BridgeBio Pharma's shares trade at USD 75.15 on Pluang as of Nov 03, 2026 19:41 WIB, showing a modest 0.21% increase for the day. Despite the positive clinical developments announced for acoramidis, Pluang order activity remains heavily skewed toward selling at 99%. The company's market cap stands at $14.61 billion, reflecting significant investor interest in the health sector stock.
